EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

System Xc-pathway as a potential regulatory target in neurological disorders

Ying Chen, Wei Xiao, Chengli Qian, Linshu Huang, Jianghao Lv, Zhuo Wang, Yi Luo

Frontiers in Pharmacology · 02.01.2026 · 16

DOI: 10.3389/fphar.2025.1701320 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.01.2026. Verfasst von Ying Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The System Xc-pathway is composed of the 12-transmembrane transporter protein SLC7A11 (xCT) and the single-channel transmembrane protein SLC3A2 (CD98hc). We detail the pathway’s characteristics and distribution within the central nervous system, as well as its canonical role in maintaining glutathione synthesis and inhibiting ferroptosis, and its emerging non-canonical functions in metabolic coupling and neuroimmunity. A core theme is the pathway’s context-dependent and often paradoxical role across major neurological disorders, including ischemic stroke, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. Critically, we analyze how pathological activation of N-methyl-D-aspartate receptors (NMDARs) can dysregulate System Xc-through mechanisms involving calcium overload, reactive oxygen species, and specific signaling axes (e.g., Nrf2, PP2A/AMPK/HMGB1), thereby exacerbating excitotoxicity and oxidative damage. Conversely, System Xc-dysfunction can further fuel NMDAR-mediated injury, creating vicious pathogenic cycles. This analysis reveals that System Xc-is not a unitary target but a dynamic node within a complex network. Consequently, effective therapeutic strategies must move beyond broad inhibition and instead aim for nuanced, cell-type-specific, and disease-stage-precise modulation. This approach will selectively correct the dysfunction of System Xc-while preserving its essential physiological roles. It presents both a significant challenge and a promising frontier for future neuroprotective drug development.

Schlagwörter

Stichwörter der Autor:innen

NMDARscentral nervous systemferroptosisglutamate excitotoxicityoxidative stresssystem Xc-

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
  • Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hubei Polytechnic Institute, School of Medical Science, Xiaogan, Hubei, China.
  • Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
  • Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
  • Hubei Provincial Clinical Research Center for Molecular Diagnostics, Wuhan, Hubei, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Xiao, W., Qian, C., Huang, L., Lv, J., Wang, Z., & Luo, Y. (2026). System Xc-pathway as a potential regulatory target in neurological disorders. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1701320

Vancouver

Chen Y, Xiao W, Qian C, Huang L, Lv J, Wang Z, et al. System Xc-pathway as a potential regulatory target in neurological disorders. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1701320

BibTeX
@article{Chen2026,
  author = {Chen, Ying and Xiao, Wei and Qian, Chengli and Huang, Linshu and Lv, Jianghao and Wang, Zhuo and Luo, Yi},
  title = {System Xc-pathway as a potential regulatory target in neurological disorders},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fphar.2025.1701320}
}
Kostenlos starten →